(Q35762280)

10 August 2017

1 reference

title

Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor (English)

1 reference

10 August 2017

1 reference

Krysten A Modrzejewski

series ordinal

1

1 reference

10 August 2017

Ronald A Herman

series ordinal

2

1 reference

10 August 2017

language of work or name

English

0 references

publication date

30 April 2004

1 reference

Annals of Pharmacotherapy

10 August 2017

published in

1 reference

10 August 2017

volume

38

1 reference

10 August 2017

issue

6

1 reference

10 August 2017

page(s)

1006-1014

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

10 August 2017

cites work

1 reference

Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.

21 January 2018

1 reference

Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase

21 January 2018

1 reference

The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1.

21 January 2018

1 reference

Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

21 January 2018

1 reference

Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro

21 January 2018

1 reference

Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type

21 January 2018

1 reference

Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

21 January 2018

1 reference

A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V

21 January 2018

1 reference

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

21 January 2018

1 reference

Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil).

21 January 2018

1 reference

Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients

21 January 2018

1 reference

Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal

21 January 2018

1 reference

A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection

21 January 2018

1 reference

South Africa to tighten control on drug trials after five death

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1D302

1 reference

10 August 2017

1 reference